InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules
VANCOUVER, British Columbia, July 02, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that it has closed the previously announced private placement. Read More